Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 11
Submit an article Journal homepage
468
Views
18
CrossRef citations to date
0
Altmetric
Letters to the Editor

Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion

Francesco CavazziniSection of Hematology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; Correspondence[email protected]
,
Enrico ListaSection of Hematology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy;
,
Francesca Maria QuagliaSection of Hematology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy;
,
Luca FormigaroSection of Hematology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy;
,
Maurizio CavallariSection of Hematology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy;
,
Sara MartinelliSection of Hematology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy;
,
Gian Matteo RigolinSection of Hematology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy;
,
Robin FoàDivision of Hematology, “La Sapienza”, University of Rome, Rome, Italy
&
Antonio CuneoSection of Hematology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy;
show all
Pages 2685-2688 | Received 03 Nov 2015, Accepted 08 Feb 2016, Published online: 21 Mar 2016

References

  • Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008;2008:450–456.
  • Visco C, Barcellini W, Maura F, et al. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol. 2014;89:1055–1062.
  • Galletti J, Cañones C, Morande P, et al. Chronic lymphocytic leukemia cells bind and present the erythrocyte protein band 3: possible role as initiators of autoimmune hemolytic anemia. J Immunol. 2008;181:3674–3683.
  • Hodgson K, Ferrer G, Montserrat E, et al. Chronic lymphocytic leukemia and autoimmunity: a systematic review. Haematologica. 2011;96:752–761.
  • Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000;95:2786–2792.
  • Moreno C, Hodgson K, Ferrer G, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood. 2010;116:4771–4776.
  • Rigolin GM, Cibien F, Martinelli S, et al. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with normal FISH: correlations with clinicobiologic parameters. FISHcorrelations with parameters. Blood. 2012;119:2310–2313.
  • Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute – Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
  • Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–13080.
  • Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–2544.
  • Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014;123:1957–1960.
  • Manda S, Dunbar N, Marx-Wood CR, et al. Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. Br J Haematol. 2015;170:734–736.
  • Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. Leukemia. 2015;30:346–50
  • Rider TG, Grace RJ, Newman JA. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia. Br J Haematol. 2015. DOI: 10.1111/bjh.13602
  • Danilov AV. Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia – response to Rider et al [letter]. Br J Haematol. 2015. DOI: 10.1111/bjh.13601.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.